• Contact us
• About us
• A-Z topics
• Symptom Checker
• Service Finder
• Linking to us
• Information partners
• Terms of use
• Privacy

Pregnancy, Birth and Baby is funded by the Australian Government and operated by Healthdirect Australia.

Pregnancy, Birth and Baby is provided on behalf of the Department of Health

Pregnancy, Birth and Baby’s information and advice are developed and managed within a rigorous clinical governance framework. This website is certified by the Health On The Net (HON) foundation, the standard for trustworthy health information.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

This information is for your general information and use only and is not intended to be used as medical advice and should not be used to diagnose, treat, cure or prevent any medical condition, nor should it be used for therapeutic purposes.

The information is not a substitute for independent professional advice and should not be used as an alternative to professional health care. If you have a particular medical problem, please consult a healthcare professional.

Except as permitted under the Copyright Act 1968, this publication or any part of it may not be reproduced, altered, adapted, stored and/or distributed in any form or by any means without the prior written permission of Healthdirect Australia.

Support this browser is being discontinued for Pregnancy, Birth and Baby

Support for this browser is being discontinued for this site

• Internet Explorer 11 and lower

We currently support Microsoft Edge, Chrome, Firefox and Safari. For more information, please visit the links below:

• Chrome by Google
• Firefox by Mozilla
• Microsoft Edge
• Safari by Apple

You are welcome to continue browsing this site with this browser. Some features, tools or interaction may not work correctly.

Bleeding during childbirth: when is it dangerous? at the time of delivery of the placenta 5-10 minutes after the birth of the baby. A woman loses 200-350 ml of blood (0.5% of body weight). Nature has foreseen such a loss.

Risk group

If a woman loses more than 400 ml of blood, doctors talk about pathological obstetric bleeding, which is already considered a complication. The risk group includes women who have already had a caesarean section (after the operation, a scar remains on the uterus, so the risk of rupture during natural childbirth increases), as well as expectant mothers expecting twins or a large baby. Other causes of bleeding during childbirth include polyhydramnios, uterine diseases (chronic endometritis, tumors), serious non-gynecological chronic ailments (diabetes mellitus, kidney failure, hepatitis) and blood clotting disorders. The age of the expectant mother can also affect the extent of blood loss: if she is over 35 years old, the risk of weakening labor activity and reducing the contractility of the uterus muscles increases.

Bleeding during childbirth may be due to problems with the placenta, rupture of the uterus or birth canal. In the first hours after the birth of the baby, a complication most often occurs due to hypotension of the uterus, when its muscles lose their tone and contractility. In each individual case, doctors act differently, but the goal is always the same - to stop blood loss as soon as possible. Fortunately, despite the fact that blood is lost quickly and in large quantities and it is not so easy to stop the process, it is still possible to minimize undesirable consequences.

Attachment point

Abundant blood loss can be caused by premature detachment of the placenta, which most often develops against the background of such a pregnancy complication as preeclampsia (in other words, preeclampsia). This disease can be accompanied by sharp jumps in blood pressure, during which the vessels in the area of ​​​​attachment of the placenta to the wall of the uterus break ahead of time, which is why profuse bleeding begins.

Medical tactics will depend on where exactly this “attachment point” is located. Normally, the placenta is attached to the upper part of the uterus, on its anterior or posterior wall. But it also happens differently. For example, if the placenta is located on the edge, opening the fetal bladder sometimes helps to stop the bleeding. When the amniotic fluid is poured out, the baby's head, sinking to the pelvic floor, presses the exfoliated area of ​​the placenta and the vessels that burst ahead of time. If the placenta is attached to the uterus in the center, an emergency caesarean section will be required.

Photo

Getty Images

Overcoming obstacles

The diagnosis of "placenta previa" means that the "attachment point" is located at the very exit, that is, at the internal os of the cervix. The main cause of improper dislocation is endometritis (a chronic inflammatory disease of the uterus), which leads to a change in the structure of the uterine mucosa. As a result, the chorion (the precursor of the placenta) is attached in the wrong place - next to the cervix. And the vessels in the area of ​​the placental site burst at the very beginning of labor, when contractions barely begin. Since the baby is still inside, the uterus cannot contract to compress the ruptured vessels, and the bleeding does not stop. Doctors can notice placenta previa even in the early stages of pregnancy, during routine ultrasounds. Careful control is established for the expectant mother, she is prescribed bed rest and sexual rest, and a planned caesarean section allows preventing blood loss at the time of childbirth.

Unexpected retention

Problems with the placenta can also occur in the third stage of labor when the placenta (placenta, membranes and umbilical cord) appears. The reason is the same - chronic inflammatory diseases of the uterus. Normally, the placenta departs 5-10 minutes after the birth of the baby. With a delay, doctors inject oxytocin, a hormone that causes uterine contractions, through a drip. If there is no result, then the placenta is attached too tightly and cannot come out on its own. In this case, the doctor separates it with his hand. This manipulation is considered an operation and is performed under intravenous anesthesia.

After the placenta appears, the midwife very carefully examines the placenta for integrity. If part of the placenta has departed, and part has remained inside, in a place where the vessels have already burst, bleeding begins, because the uterus can contract properly only after the placenta is completely born. Manual separation of the placenta and removal of the placenta again helps to correct the situation.

High voltage

Bleeding can also start due to rupture of the birth canal in the first stage of labor, when, not listening to the recommendations of the midwife, the woman begins to push ahead of time. But if you strictly follow all the instructions of the doctors, this trouble can be avoided. In the second stage of labor, the main causes of bleeding (except for cervical rupture) may be perineal or clitoral tears. To prevent rupture of the perineum, an episiotomy or perineotomy is done (an incision in the perineum at the height of the contraction).

Last effort

If the delivery was prolonged, hypotonic bleeding may develop in the first two hours after the baby is born. The muscles of the uterus get very tired and do not respond to oxytocin, do not contract; accordingly, bursting vessels are not pinched. If an additional dose of oxytocin does not help, a "control manual examination of the walls of the uterus" is performed, designed to cause its reflex contractions. The doctor inserts one hand into the vagina, puts the other on the stomach and tries to compress the uterus from both sides. If the bleeding does not stop, the anterior abdominal wall is cut under general anesthesia and the iliac arteries are ligated.

Photo

Getty Images/iStockphoto

Express method

For heavy bleeding, a rapid hemoglobin test is performed. If the indicators fluctuate within acceptable limits, the volume of fluid in the vessels is restored using special solutions (saline, glucose, etc.). When the hemoglobin level is very low, a blood transfusion is required. For prevention purposes, drugs that increase blood clotting are also used.

More useful materials for expectant mothers - in our channel on Yandex.Zen.

Lyubov Prishlaya

Reading today

“The mother-in-law constantly compares her grandson with someone else's child. What is she up to?

Reluctant child prodigy: how the closest people prepared for Nika Turbina a truly tragic fate

4 tips on how to end a relationship without a future0003

Survived the loss of a child, hid her daughter for 5 years: 8 facts from the life of Victoria Isakova

Prevention of obstetric bleeding in high-risk patients. Modern treatment tactics

Postpartum haemorrhage (PPH) is a life-threatening complication of spontaneous and operative delivery, one of the main factors of maternal morbidity and mortality both in developing countries and in countries with a low level of economic development. PPH occurs with a frequency of approximately 6% in all types of childbirth [1-4] and is associated with a number of severe conditions accompanied by a large amount of blood loss (severe anemia, heart failure, sepsis).

According to I.S. Sidorova [4], during pregnancy against the background of preeclampsia, the production of prostacyclin decreases and the secretion of a powerful vasoconstrictor and aggregant, thromboxane, increases. This leads to the occurrence of a generalized vascular spasm with the addition of a hypercoagulable syndrome. HELL. Makatsaria et al. [5] and T.A. Fedorova et al. [6] noted pronounced shifts in the hemostasis system towards hypercoagulation and an increase in the level of paracoagulation products characteristic of disseminated intravascular coagulation (DIC) during pregnancy against the background of preeclampsia. E.B. Canes et al. [7] classify pregnant women with severe forms of preeclampsia as a group of especially dangerous obstetric hemorrhages.

The consequence of obstetric bleeding can be not only DIC, but also a number of other equally severe complications such as cardiovascular and renal failure, HELLP syndrome, and Sheehan's syndrome (postpartum pituitary necrosis) [8, 9]. Thus, the pathogenetic basis of disorders of the hemostasis system consists in the generalization of the process of intravascular thrombosis with subsequent depletion of anticoagulant factors and the development of severe coagulopathic disorders, so even a slight excess of physiological blood loss can trigger the development of DIC [4].

According to G.M. Savelyeva et al. [10], blood loss of more than 1000 ml (more than 25% of the circulating blood volume (CBV) or more than 1.5% of body weight) leads to the development of hemorrhagic shock. However, according to S.P. Lysenkova et al. [11], even with a blood loss of up to 20% of the BCC, changes characteristic of DIC can be observed in the hemostasis system: a short-term hypercoagulation phase is replaced by a hypocoagulation phase. Some domestic authors [5, 10] believe that hypercoagulation syndrome and hypovolemia, which are characteristic of the course of pregnancy against the background of preeclampsia, reduce the tolerance of the female body in the event of obstetric bleeding, and also lead to a breakdown in compensatory capabilities and the appearance of symptoms of shock and with less blood loss. In severe forms of preeclampsia, multiple organ failure and endogenous intoxication develop, which can lead to the death of the mother and / or fetus.

Caesarean section (CS) is a recognized risk factor for the development of PPH, with the proportion of operative deliveries in recent years increasing to 20–30% in most developed countries and up to 40% in China [12, 13]. Despite the introduction of new methods of treatment into clinical practice, anomalies of labor activity are one of the main reasons for performing operative delivery, approximately every third CS is performed for anomalies of labor forces [14, 15].

According to foreign researchers [12, 13], in the structure of indications for abdominal delivery, the scar on the uterus predominates, its share is 15-38.2%, followed by preeclampsia - 16%, dystonia in childbirth - 13.4-42%, fetal distress - 10.9-19%. These indicators indicate that the interests of the fetus are considered as the leading reasons for performing CS in almost 80% of cases of operative delivery.

In recent decades, there has been a fairly clear trend towards a significant expansion of indications for CS, in turn, an increase in the frequency of CS performed can significantly reduce perinatal losses [16, 17]. The frequency of CS in the Russian Federation is 15-16%, reaching 30-40% in perinatal centers. The upward trend in this indicator is due to changing indications for surgery, among which in the last decade, “relative in the interests of the fetus” has been a priority [16, 18]. The implementation of delivery by CS and the performance of organ-preserving operations on the uterus contributed to an increase in the number of women of reproductive age with an operated uterus. At the same time, the management of subsequent pregnancies and childbirth in these patients is a complex problem. Re-K.S. not only requires large material costs, but also increases the risk of intra- and postoperative complications. At the same time, the level of maternal morbidity and mortality in this contingent of women is significantly higher than those after spontaneous delivery and the first CS [2, 19].

The frequency of massive obstetric bleeding after CS is higher than after vaginal delivery, which causes some concern for specialists due to the steady increase in the proportion of planned and emergency CS in the total number of births. At the same time, some risk factors for the need to perform a CS are simultaneously risk factors for the development of PPH [20]. The high incidence of complications after CS necessitates the improvement of methods for their prevention. For this purpose, intravenous drip slow administration of oxytocin has been used for a long time [21, 22]. However, this drug has a short half-life (10–15 min) in the body both during the operation and in the early postoperative period. At the same time, it is during this period that the maximum frequency of PPH is observed [20, 22].

Thus, the problem of ensuring safe and effective prevention of PPH during operative delivery by CS is topical. In clinical practice, a wide range of methods for the prevention of PPH is used; therefore, a clear algorithm of actions is needed that would provide an optimal result.

The purpose of the study was to analyze the literature data on the use of carbetocin for the treatment of obstetric bleeding after CS.

WHO currently recommends active management of the third stage of labor to prevent PPH. As part of this set of measures for the prevention of PPH, the following actions are carried out:

1) administration of a uterotonic preparation immediately after the birth of the child;

2) controlled pulling of the umbilical cord to deliver the placenta;

3) massage of the fundus of the uterus after the birth of the placenta [23].

In this case, the introduction of uterotonic drugs immediately after the birth of the child is considered the most important stage. Oxytocin is considered as a recommended drug when used in conditions where its effectiveness is beyond doubt [24]. Drugs from the group of uterotonic drugs play an important role in obstetrics, in particular in the implementation of labor activation and labor induction, as well as in the prevention and treatment of PPH. Regardless of the indications, when using uterotonic drugs, specialists achieve the optimal combination of efficacy and safety of their use, taking into account the characteristics of specific drugs, their dosages, routes of administration, clinical indications and contraindications for their use, as well as the individual characteristics of the patient [25].

Oxytocin (10 IU IV or IM) is recommended as the uterotonic drug of choice. WHO and other organizations recommend storing oxytocin at a temperature of 2–8 °C in order to prevent the destruction of the active substance and maintain the effectiveness of the drug [26].

Synthetic oxytocin has been widely used in obstetric practice since the 1960s. For decades, a search has been made for a uterotonic drug with a more stable active substance to increase the effectiveness of its use. A more modern analogue of oxytocin is carbetocin, a drug that also acts on oxytocin receptors in the myometrium. According to a number of characteristics, this drug differs significantly from synthetic oxytocin - its half-life is much longer, the drug is more thermostable.

According to experts [12, 13, 25], the current lack of effective uterotonic drugs is a key obstacle to a significant reduction in maternal mortality in most countries of the world.

Currently, oxytocin and syntometrine (combination preparation containing 5 IU of oxytocin and 0.5 mg of ergometrine) are predominantly used to prevent PPH. Synthometrine acts quite quickly due to oxytocin and has a stable uterotonic effect due to ergometrine. Despite the fact that the prophylactic use of syntometrine in the III stage of labor effectively reduces blood loss and the frequency of PPH, the use of this drug leads to the development of adverse events from the cardiovascular (CVS) and digestive systems. So, when using syntometrine, nausea, vomiting and an increase in blood pressure can be observed, primarily due to the activation of smooth muscle contraction and vasoconstriction, therefore syntometrin is contraindicated in preeclampsia and in the presence of a number of concomitant diseases, in particular CCC. Oxytocin is administered to such patients, although this drug is less effective in preventing PPH [27].

In recent years, prostaglandins such as misoprostol and carboprost have been actively studied for the prevention of PPH. Misoprostol is less effective than parenteral uterotonic drugs in preventing PPH after spontaneous delivery, and its use is associated with a higher incidence of severe PPH and the need for additional uterotonic drugs [28], making misoprostol unsuitable for the prevention of PPH.

It should be noted that the effectiveness of uterotonic drugs in the prevention of PPH may be reduced under conditions that lead to degradation of the active substance. In a number of low- and middle-income countries, where it is not possible to provide the necessary conditions for transporting and storing the drug at all stages, the effectiveness of oxytocin cannot be guaranteed, since it decomposes under the influence of temperature [28]. To date, the fact of destruction of oxytocin under the influence of temperature is well known [29, thirty]. It has been shown that up to 45.6% of oxytocin samples do not pass quality assessment tests, primarily due to the insufficient content of the active substance in finished dosage forms [31]. Another study confirmed the low quality of uterotonic drugs in a number of countries around the world [32]. This study showed that 74.2% of injectable oxytocin samples and 33.7% of misoprostol samples did not meet the required quality level [32, 33].

Relatively common are ergometrine or methylergometrine, misoprostol, and fixed-dose combinations. Ergometrine is degraded when exposed to heat or light, while misoprostol is rapidly degraded when exposed to moisture [34]. The degradation of the active substance leads to a decrease in its concentration and to a decrease in the effectiveness of the drug.

Recent studies state that oxytocin has “unsatisfactory actual efficacy in real clinical practice due to temperature sensitivity” [30]. However, this suggestion is based solely on an estimate of the amount of pharmacologically active substance in the samples, and not on data on the effectiveness of the drug obtained in clinical studies on patients.

It has been shown that the route of administration of the drug is of great importance for the effectiveness of drugs in the prevention of PPH [31, 34]. Thus, in a double-blind study that evaluated the comparative efficacy of oxytocin at a dose of 10 IU intravenously and intramuscularly, significant differences were shown in the parameters used as clinically significant endpoints. The success rate for the prevention of blood loss equal to or greater than 1000 cm3 ³ , defined as an adjusted odds ratio (aOR), was 0.54 (95% confidence interval (CI) 0.32-0.91), the indicator of the reduction in the need for blood transfusion is OR 0.31 (95% CI 0.13-0.70), i.e. the effectiveness of the drug when administered intravenously higher than with intramuscular [35].

Along with this, differences were found when using the drug in doses of 5 and 10 I.U. Thus, a pooled analysis of the results with blood loss equal to or more than 500 cm ³ as an end point showed that the effectiveness of oxytocin at doses of 5 and 10 IU is comparable, the OR values ​​were 0. 42 (95% CI 0.17–1.01) and 0.47 (95% CI 0.38–0.59) [36].

In the 1990s, carbetocin, a synthetic analog of human oxytocin with structural modifications, was proposed for use in clinical practice, prolonging its half-life in the body, which in turn increases the duration of the drug effect by 4–10 times [12, thirty]. The data available to date suggest a higher efficacy of carbetocin as a drug for the prevention and treatment of PPH compared with oxytocin and other drugs and their combinations [35].

Carbetocin is a long-acting synthetic analogue of oxytocin that can be administered as a single intravenous or intramuscular injection. When studying the pharmacodynamic characteristics of the drug, it was found that intravenous administration of carbetocin led to the development of tetanic contraction of the uterus for 2 minutes, followed by rhythmic contractions for 1 hour. Intramuscular administration of the drug was accompanied by the development of tetanic contraction of the uterus for 2 minutes lasting about 11 minutes, followed by rhythmic within 2 h [36].

It has been established that carbetocin, when administered in the postpartum period, has a longer duration of action than oxytocin and causes more frequent contractions of greater amplitude [37].

Optimization of the production of carbetocin preparations has resulted in a product that meets the requirements of the International Council for the Harmonization of Specifications for Medicinal Products for Human Use (ICH) for hot and humid climates (zones IVA and B) for 36 months at 30 °C and for 6 months at a temperature of 40 °C [36]. In countries where refrigeration is not available at all stages of storage and transport, carbetocin, used as a safe uterotonic drug that is stable at higher temperature and humidity, may help reduce maternal mortality from PPH.

This drug is more stable and causes a prolonged uterine response when the drug is administered in the postpartum period. The drug manufacturer has developed a stable version of the molecule (heat-resistant carbetocin, formerly carbetocin RTS), which can potentially be used in countries where it is difficult to provide the necessary conditions (including temperature) during delivery and storage [36-39].

However, to date, the drug is not among the uterotonic drugs recommended by WHO for the prevention of PPH. This is primarily due to its unconfirmed efficacy in the prevention of PPH after vaginal delivery.

As is known, in addition to clinical efficacy, the most important characteristic of all drugs is their safety. At the same time, it should be taken into account that oxytocin and other uterotonic drugs are often used in unsafe conditions (the drug is administered until mechanical obstacles to head advancement are eliminated, intramuscularly or intravenously as a bolus, without careful monitoring of labor activity and in the absence of an opportunity to perform an emergency CS) [40]. Such unsafe use of these drugs has a significant impact on the incidence of adverse birth outcomes, significantly increasing their level in a number of countries in Asia and in some other regions [41, 42].

Carbetocin is not a safer drug in this respect. Perhaps, given the longer half-life of carbetocin, its wider use instead of oxytocin will increase the risk of adverse outcomes associated with misuse, in particular acute fetal hypoxia and uterine rupture.

One cannot ignore such characteristics of the considered group of drugs as their availability and cost. Thus, oxytocin is a relatively cheap and widely available drug, but in a number of countries generic drugs (generics) on the market often do not meet modern international quality standards. Of course, in order for carbetocin to be considered as a suitable alternative to oxytocin, it is necessary that the drug be equally cheap and widely available. Carbetocin manufacturer Ferring Pharmaceuticals (Switzerland) intends to make the drug “available in public sector institutions in countries with a high disease burden at an affordable price”, but at the moment this program is far from the declared level of its implementation [43].

To date, data from clinical studies have been obtained that have confirmed that the drug can be used at a dose of 100 micrograms intravenously or intramuscularly for the prevention of bleeding after CS. At the same time, it is considered that carbetocin should be used in conditions of abdominal delivery in the presence of at least one risk factor for bleeding, including placenta previa, in the presence of signs of placental rotation, chorioamnionitis, more than one CS in history, duration of an anhydrous period of more than 24 hours, multiple pregnancy , estimated fetal weight of more than 4500 g, a history of PPH with plasma or blood transfusion, severe anemia, thrombocytopenic purpura [44, 45].

In August 2018, the New England Journal of Medicine presented the results of a large-scale international study comparing the effectiveness of carbetocin and synthetic oxytocin in the prevention of postpartum hemorrhage [30]. Based on the publication of the results of the study, some experts said that the use of carbetocin "will lead to a revolution in the prevention of maternal death." Although this statement seems to be an exaggeration, a number of clinical studies have been conducted to date on the effectiveness of carbetocin in the prevention of PPH after spontaneous delivery, including a controlled study "Heat Stable Carbetocin for preventing postpartum haemorrhage: a randomized non-inferiority ” with the participation of 30,000 patients [46] and “Intramuscular Oxytocics: A Comparison Study of Intramuscular Carbetocin, Syntocinon and Syntometrine for the Third Stage of Labor Following Vaginal Birth (IMox) — North Bristol NHS Trust” with the participation of 6285 patients [47]. Based on the results of these studies, the necessary rationale is provided for the inclusion of (thermostable) carbetocin in the global recommendations in response to the need for additional methods for the prevention of PPH [48].

Carbetocin is increasingly being used to prevent PPH after CS. Studies of the possibility of using carbetocin during CS have shown a high clinical efficacy of the drug in the prevention of PPH, while the safety of the drug is similar to that of oxytocin. The purpose of the study L. Su et al. [49] studied the effectiveness of intramuscular uterotonic drugs, as well as a comparison of the frequency and severity of side effects and the cost of carbetocin, oxytocin and fixed-dose oxytocin/ergometrine (syntometrine) combined preparations. All preparations were refrigerated throughout the study in accordance with the blinded study design. The study is particularly important because it also evaluated the combination oxytocin/ergometrine, which is widely used in the prevention of PPH due to its high efficacy, but its use is associated with a number of side effects.

It is believed that carbetocin should be used in puerperas with abdominal delivery and with at least one or more risk factors for postpartum haemorrhage [27, 43]. Reports of RCTs conducted to date indicate that to prevent bleeding after CS, the drug should be used at a dose of 100 μg intravenously or intramuscularly [30, 50, 51].

The aim of the study I. Gallos et al. [48] ​​evaluated the clinical efficacy and safety of uterotonic drugs for the prevention of PPH, followed by the creation of a rating of available uterotonic drugs for use in clinical practice in accordance with efficacy and side effects. The science-based rating is intended to determine the most effective drug for the prevention of PPH.

The authors compared all uterotonic drugs and their combinations for the prevention of PPH (oxytocin, misoprostol, ergometrine, carbetocin, oxytocin + misoprostol, oxytocin + ergometrine) with placebo and no such treatment group. The meta-analysis included data from all RCTs and cluster studies that examined the efficacy and/or safety of these drugs for the prevention of PPH. The use of uterotonic drugs in the III stage of labor for the prevention of PPH was evaluated when compared with a control uterotonic drug, with placebo or no treatment. The target group included patients after operative delivery or spontaneous delivery that occurred in the hospital and out of hospital. According to the results of the study, the combinations of ergometrine + oxytocin, misoprostol + oxytocin, as well as the drug carbetocin, were shown to be more effective in preventing PPH with a volume of more than 500 ml. It was shown that the combination of ergometrine + oxytocin was the most effective in preventing PPH with a volume equal to or more than 1000 ml, and carbetocin was characterized by maximum safety - it had the most favorable side effect profile among the most effective drugs and their combinations.

The aim of the study by M. Widmer et al. [46], evaluated the effectiveness of thermostable carbetocin at a dose of 100 μg intramuscularly compared with oxytocin at a dose of 10 IU in the prevention of PPH after spontaneous delivery. Postpartum administration of this uterotonic drug has been shown to reduce the incidence of hypotonic PPH. According to the authors, most of the deaths of PPH can be avoided by the prophylactic administration of uterotonic agents during the third stage of labor.

Another meta-analysis compared the efficacy of carbetocin and oxytocin as uterotonic agents after spontaneous labor and operative delivery in 8 studies. In all studies, carbetocin was administered at a standard dose of 100 µg. The total dose of oxytocin ranged from 5 to 32.5 IU. Most head-to-head studies showed that the risk of PPH was not significantly reduced with carbetocin compared with oxytocin, with an hazard ratio (RR) of 0.66 (95% CI 0.42-1.06). However, the use of carbetocin is associated with significantly less need for additional uterotonic drugs (RR 0.68; 95% CI 0.55–0.84) and uterine massage (RR 0.54; 95% CI 0.31– 0.96). A comprehensive evaluation of efficacy showed that the risk of massive PPH (blood loss equal to or more than 1000 ml in the III stage of labor) against the background of carbetocin and oxytocin does not differ (RR 0. 91; 95% CI 0.39-2.15). With regard to the frequency of blood transfusions, OR levels were less than 1, while there were no statistically significant differences [51].

A comparative meta-analysis of the incidence of side effects of carbetocin and oxytocin showed that the risk of side effects (nausea, vomiting, "hot flashes", headache, fever, tremor, abdominal/back pain, metallic taste in the mouth, sweating, shortness of breath and dyspnea, tachycardia, drop in blood pressure, itching, chills and decreased visual acuity) in patients after CS was comparable, except for the incidence of dizziness (RR 0.31; 95% CI 0.12-0.83). No statistically significant differences were shown after vaginal delivery for PPH rates (RR 0.95; 95% CI 0.43–2.09), the need for therapeutic uterotonics (RR 0.95; 95% CI 0.43–2.09), and the incidence of side effects of carbetocin and oxytocin. At the same time, the need for uterine massage with the introduction of carbetocin is significantly lower compared with oxytocin (RR 0. 70; 95% CI 0.52-0.94). There were no statistically significant differences in assessments in terms of blood loss, the level of decrease in hemoglobin and uterine tone after the administration of carbetocin and oxytocin after surgical and spontaneous labor [51].

O. Reyes and G. Gonzalez [50] conducted a comparative study of the efficacy of carbetocin and oxytocin in patients with severe preeclampsia after spontaneous or operative delivery. Carbetocin and oxytocin have been shown to be equally effective in the prevention of PPH, with carbetocin being a safe drug, making it a suitable alternative to oxytocin as it appears to have no clinically significant hemodynamic effects in massive PPH.

M. Moertl et al. [52] specifically investigated the hemodynamic effects of carbetocin versus oxytocin after C.S. Both drugs have been shown to have comparable hemodynamic effects as measured by heart rate, systolic and diastolic blood pressure levels, and total peripheral vascular resistance, and have an acceptable safety profile for prophylactic use. In addition, a meta-analysis of 2 studies showed that against the background of carbetocin, the risk of developing arterial hypertension after spontaneous delivery is significantly lower than against the background of syntometrine.

The purpose of the study L.D. Belotserkovtseva et al. [53] compared the efficacy of carbetocin and oxytocin in preventing PPH in high-risk patients with abdominal delivery. According to the results of the study, equally high efficiency of the applied schemes was demonstrated. At the same time, it was found that significantly more women needed additional uterotonics in the postoperative period in the oxytocin group (43.6% compared to 97.3%). The volume of blood loss over 1000 ml was registered in 6 (2.8%) patients of the group in which carbetocin was used, and in 4 (2.2%) when using oxytocin. There was one case of hysterectomy in each group (0.5% each).

Ligation of the internal iliac arteries was used as the most common method of the surgical stage of bleeding control, which was performed in 22 (10. 1%) cases with carbetocin and in 13 (7.0%) with oxytocin. Most often, as an indication for ligation of blood vessels, the authors considered the presence of placental abruption or placenta previa. Compression sutures on the uterus, plasma and blood transfusions, as well as reinfusion of autoplasma and autoerythrocytes were performed with a similar frequency. Carbetocin has been shown to be effective in preventing bleeding in 97.2% of cases when performing CS in high-risk pregnant women. At the same time, the need for additional prescription of uterotonic drugs in the postoperative period decreased by more than 2 times.

It is generally accepted that the incidence of postpartum haemorrhage, which is the leading cause of maternal morbidity and mortality, is higher with operative CS than with vaginal delivery. At the same time, the share of CS in the total number of births, most likely, will only grow in the foreseeable future. Currently, approaches to the prevention of postpartum hemorrhage differ significantly, and therefore, based on the evidence and the results of expert consensus, guidelines are being developed to select the most safe and effective treatment tactics for emergency CS.

Certainly, carbetocin is one of the drugs that act on the myometrium, which is considered as a potentially important tool to improve birth outcomes. There is a possibility that carbetocin will partially replace some other drugs in certain clinical situations. However, the need for oxytocin, misoprostol, tranexamic acid and ergot alkaloids will remain. The optimal strategy for the use of uterotonic drugs depends on the specific clinical setting. It is necessary to take into account the characteristics of the drugs used, the available data on efficacy and safety, as well as the peculiarities of the region in which the drug is used.

Heat-resistant carbetocin is currently being studied as a potential alternative to oxytocin for the prevention of PPH. It is likely that the results of the studies will become the basis for the revision of WHO recommendations on the prevention and treatment of bleeding: carbetocin may be included in the recommendations as a means of preventing postpartum hemorrhage. It is believed that the drug can also be included in the WHO list of essential medicines used for this purpose, if it is not possible to ensure optimal storage and transportation conditions for other uterotonic drugs. However, there are only a few reports in the literature about this approach to the prevention and treatment of bleeding during surgical delivery. Clear indications for the use of carbetocin in pregnant women with a high risk of bleeding have not been developed, there are no data from evidence-based studies of the efficacy and safety of this drug in this group of patients. Changes in the hemostasis system in pregnant women with the use of carbetocin, as well as the effect of the drug on hematological and biochemical parameters in women with a high risk of postpartum hemorrhage, have not been characterized, the effect of the use of this drug on the need for additional use of uterotonics in the postoperative period has not been evaluated.

Studies conducted to date have shown that the incidence of side effects when using carbetocin is not higher than that when using oxytocin, the drug is no less effective than syntometrine, therefore it can become an alternative uterotonic agent for the prevention of postpartum hemorrhage after spontaneous labor and operative delivery.

However, despite the established efficacy and safety of carbetocin after CS, additional studies are needed to clarify the safety profile of this drug in the presence of concomitant diseases in parturient women, in particular arterial hypertension and other diseases of the cardiovascular system. It is also necessary to conduct studies aimed at clarifying the minimum effective dose of carbetocin, assessing the clinical and economic aspects of its use in the practice of obstetric medical institutions.

The authors declare no conflict of interest.

The authors declare no conflict of interest.

Credits

Babloyan A.G. — Postgraduate student of the Department of Obstetrics and Gynecology, Moscow State University of Medicine and Dentistry. A.I. Evdokimov” of the Ministry of Health of Russia, Moscow, Russia; https://orcid.org/ 0000-0001-6618-5077

Tsakhilova S.G. – MD, prof. FGBOU VO Moscow State University of Medicine and Dentistry named after A. I. A.I. Evdokimov” of the Ministry of Health of Russia, Moscow, Russia; https://orcid.org/0000-0002-4898-6919

Sakvarelidze N.Yu. – Candidate of Medical Sciences, Assoc. Department of Obstetrics and Gynecology, Moscow State University of Medicine and Dentistry named after A.I. A.I. Evdokimov” of the Ministry of Health of Russia, Moscow, Russia; https://orcid.org/ 0000-0002-9041-6055

Pihut P.P. — Postgraduate student of the Department of Obstetrics and Gynecology, Moscow State University of Medicine and Dentistry. A.I. Evdokimov” of the Ministry of Health of Russia, Moscow, Russia; https://orcid.org/ 0000-0002-0716-955X

Zykova A.S. — Senior laboratory assistant of the Department of Obstetrics and Gynecology, Moscow State University of Medicine and Dentistry. A.I. Evdokimov” of the Ministry of Health of Russia, Moscow; https://orcid.org/0000-0001-9577-4815

Morgoeva A.A. — Postgraduate student of the Department of Obstetrics and Gynecology, Moscow State University of Medicine and Dentistry.

Learn more

• 
  How to regrow hair after pregnancy
• 
  How long to get pregnant with pcos
• 
  Cramping ovaries early pregnancy
• 
  What does endo mean in medical terms
• 
  How do you find a child in foster care
• 
  Why do pregnant women get swollen feet
• 
  How to measure child feet
• 
  Itching all over during pregnancy
• 
  How much to raise a child in australia
• 
  Treatment miscarriage 6 weeks
• 
  White dots on baby skin